http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20020015997-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14 |
| filingDate | 2000-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20020015997-A |
| titleOfInvention | Substituted Purine Derivatives As Inhibitors of Cell Adhesion |
| abstract | The present invention also relates to the use of a compound of formula I wherein B, D, E, G, X, Y, Z, R 1 , R 2 and s have the meanings indicated in the claims, their physiologically acceptable salts and It is about his prodrug. The compounds of formula I are valuable pharmacologically active compounds. They are inhibitors of bitronectin receptor antagonists and cell adhesion and are based on the interaction between the bitonectin receptor and its ligand in the cell-cell or cell-substrate interaction process and are capable of preventing, alleviating or treating such interactions It is suitable for the treatment and prevention of diseases. For example, they can be applied to inhibit osteoclast-induced bone resorption, and thus can be applied to the treatment and prevention of osteoporosis, or to inhibit undesirable angiogenesis or cell proliferation of vascular smooth muscle tissue. The present invention further relates to a process for the preparation of a compound of formula (I), its use, in particular its use as an active ingredient in medicaments, and pharmaceutical compositions containing it. |
| priorityDate | 1999-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 321.